Published in MAbs on August 11, 2015
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 5.10
Improving biosensor analysis. J Mol Recognit (2000) 4.83
Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (2010) 4.47
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem (2002) 4.11
Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov (2009) 3.66
Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med (2012) 3.61
Germline transformation of the silkworm Bombyx mori L. using a piggyBac transposon-derived vector. Nat Biotechnol (2000) 3.09
Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol (2008) 2.52
Transgenic silkworms produce recombinant human type III procollagen in cocoons. Nat Biotechnol (2002) 2.42
Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J (1999) 2.40
Marketed therapeutic antibodies compendium. MAbs (2012) 2.26
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol (2006) 1.95
Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol (2001) 1.86
Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods (2002) 1.85
Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood (1989) 1.80
CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol (2011) 1.79
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology (2003) 1.72
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology (2006) 1.69
High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology (2011) 1.68
Neonatal Fc receptor and IgG-based therapeutics. MAbs (2011) 1.56
Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol (2003) 1.51
Production of antibodies in plants: status after twenty years. Plant Biotechnol J (2010) 1.49
Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog (2005) 1.49
Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol (1982) 1.47
Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs (2010) 1.37
Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet (2012) 1.37
Production of pharmaceutical proteins by transgenic animals. Comp Immunol Microbiol Infect Dis (2008) 1.33
The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol (1995) 1.29
Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol (2005) 1.25
In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J (2007) 1.19
Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev (2012) 1.17
Production of a recombinant mouse monoclonal antibody in transgenic silkworm cocoons. FEBS J (2009) 1.10
The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs (2015) 1.10
Silkworm expression system as a platform technology in life science. Appl Microbiol Biotechnol (2010) 1.09
The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol (2012) 1.06
Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Mol Genet Metab (2014) 1.04
Protein N-glycosylation in the baculovirus-insect cell system. Curr Drug Targets (2007) 1.03
Transgenic silkworms that weave recombinant proteins into silk cocoons. Biotechnol Lett (2010) 1.00
The significance of glycosylation analysis in development of biopharmaceuticals. Biol Pharm Bull (2009) 0.99
The generation of germline transgenic silkworms for the production of biologically active recombinant fusion proteins of fibroin and human basic fibroblast growth factor. Biomaterials (2006) 0.98
Generation of a transgenic silkworm that secretes recombinant proteins in the sericin layer of cocoon: production of recombinant human serum albumin. J Biotechnol (2006) 0.98
Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J (2012) 0.97
Transgenic milk as a method for the production of recombinant antibodies. J Immunol Methods (1999) 0.96
Use of transgenic animals in biotechnology: prospects and problems. Acta Naturae (2013) 0.96
With or without sugar? (A)glycosylation of therapeutic antibodies. Mol Biotechnol (2013) 0.95
Increased serum clearance of oligomannose species present on a human IgG1 molecule. MAbs (2012) 0.94
Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem (1990) 0.93
Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol (2013) 0.92
Construction of a binary transgenic gene expression system for recombinant protein production in the middle silk gland of the silkworm Bombyx mori. Transgenic Res (2009) 0.92
Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol (2008) 0.91
The silkworm-an attractive BioResource supplied by Japan. Exp Anim (2010) 0.89
First US approval for a transgenic animal drug. Nat Biotechnol (2009) 0.89
The production of biopharmaceuticals in plant systems. Biotechnol Adv (2009) 0.89
Glyco-engineering for biopharmaceutical production in moss bioreactors. Front Plant Sci (2014) 0.87
Human IgG1 expression in silkworm larval hemolymph using BmNPV bacmids and its N-linked glycan structure. J Biotechnol (2008) 0.86
Expression systems and species used for transgenic animal bioreactors. Biomed Res Int (2013) 0.85
Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies. PLoS One (2014) 0.84
Monoclonal antibody expression in mammalian cells. Methods Mol Biol (2012) 0.82
Human therapeutic proteins from silkworms. Nat Biotechnol (2003) 0.81
Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.81
Comparative in vitro and experimental in vivo studies of the anti-epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants. Plant Biotechnol J (2012) 0.79
Transient and stable expression of antibodies in Nicotiana species. Methods Mol Biol (2012) 0.79
Homogeneous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization of the product. J Vet Med Sci (1993) 0.79
European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Clin Appl Thromb Hemost (2009) 0.78
Effect of ATG initiation codon context motifs on the efficiency of translation of mRNA derived from exogenous genes in the transgenic silkworm, Bombyx mori. Springerplus (2014) 0.78
Comparison of recombinant protein expression in a baculovirus system in insect cells (Sf9) and silkworm. J Biochem (2010) 0.77
Silkworm as a host of baculovirus expression. Curr Pharm Biotechnol (2010) 0.76
Taliglucerase alfa for the treatment of Gaucher's disease. Drugs Today (Barc) (2012) 0.76
Improved secretion of molecular chaperone-assisted human IgG in silkworm, and no alterations in their N-linked glycan structures. Biotechnol Prog (2010) 0.76
Production of canine IFN-gamma in silkworm by recombinant baculovirus and characterization of the product. J Interferon Cytokine Res (2000) 0.75